Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254834 | 0.98 | MEN1 (0.42) | EPHX2CASP2CA12CA1CA2 | |
| SCHEMBL14471253 | 0.98 | MEN1 (0.42) | EPHX2CASP2CA12CA1CA2 | |
| SCHEMBL17276977 | 0.92 | TSHR (0.44) | CASP2CA12CA1CA2CA4 | |
| SCHEMBL15132494 | 0.91 | EPHX2 (0.41) | EPHX2CASP2CA12CA1CA2 | |
| SCHEMBL15492671 | 0.90 | MEN1 (0.47) | EPHX2CASP2CA12CA1CA2 | |
| SCHEMBL20327891 | 0.89 | MEN1 (0.41) | EPHX2CASP2CA12CA1CA2 | |
| SCHEMBL13598099 | 0.89 | MEN1 (0.41) | EPHX2CASP2CA12CA1CA2 | |
| SCHEMBL15177572 | 0.89 | TSHR (0.49) | EPHX2CASP2TSHRNAAACNR1 | |
| SCHEMBL20149314 | 0.89 | TSHR (0.41) | CASP2CA12CA1CA2CA4 | |
| SCHEMBL23267578 | 0.88 | TSHR (0.47) | EPHX2CASP2TSHRNAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3721943-A1 | LIPIDS, LIPID COMPOSITIONS AND METHODS OF USING THEM | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| EP-3542789-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GlaxoSmithKline Biologicals SA (BE) | 2019-09-25 | — | — | EP | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802773-B2 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | Arrowhead Madison Inc. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130190484-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
| WO-2012031046-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011076807-A2 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-7351790-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | EPHX2 388/4885CASP2 2268/4885CA12 1111/4885 |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NSUN3, RNMT, AGO2 | EPHX2 3551/4885CASP2 3559/4885CA12 4218/4885 |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | EPHX2 388/4885CASP2 2268/4885CA12 1111/4885 |
| US-20130190484-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | RNASE1, PNKP, POLM | EPHX2 2337/4885CASP2 3364/4885CA12 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.